Local ICU AI Teaching Agent to Support Rotating Residents
Official title: Effect of a Localized ICU-Specific AI Teaching Agent on Institutional Workflow Mastery and Clinical Competency in Rotating ICU Residents: A Single-Center, Parallel-Group, Randomized Controlled Superiority Trial
Run by Peking Union Medical College Hospital · NCT07692035 · Data updated 2026-11-12
A new AI tutor designed for a single center is being tested to see if it reduces cognitive load and improves ICU protocol task performance for first-time rotating residents.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 20, 2026 |
| Main results expected | June 30, 2026 |
| Study ends | July 5, 2026 |
| Registry record updated | July 9, 2026 |
| Trial ID | NCT07692035 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
First-time ICU rotating residents with at least 4 consecutive weeks of ICU training and ability to use AI tools on clinical devices.
✕Probably not a fit
Residents with substantial prior ICU experience or those not benefiting from AI-assisted learning may see little to no improvement.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pragmatic, parallel-group randomized trial compares an institution-specific, protocol-bound AI teaching agent (ICU-Tutor) with unrestricted general-purpose AI tools. Conducted in the ICU teaching wards at Peking Union Medical College Hospital, it targets first-time rotating residents during their initial ICU rotation. The study uses a 1:1 randomization to assess whether ICU-Tutor can lower extraneous cognitive load and enhance standardized protocol performance over a 14-day period. Eligible participants will be screened, consented, and assessed at Day 3, Day 7, and Day 14 after randomization. The trial operates within routine clinical education settings and adheres to site-specific ICU protocols and workflows.
Why it matters
Potential benefit: If successful, residents may learn faster with less cognitive strain and perform ICU tasks more accurately according to local guidelines.
How similar studies have gone: Previous studies show mixed results for AI learning aids; this trial tests a site-specific AI agent designed to align with local protocols, which is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. First-time rotating residents with no prior formal ICU clinical rotation experience 2. Scheduled to complete a minimum of 4 consecutive weeks of ICU training 3. Able to complete all scheduled assessments at Day 3, Day 7, and Day 14 post-randomization 4. Possess basic digital literacy to operate assigned AI tools on standard clinical devices 5. Voluntarily provide written informed consent to participate in the trial Exclusion Criteria: 1. Cumulative prior formal ICU clinical experience exceeding 7 calendar days 2. Regular daily clinical use of AI tools for medical decision-making in the 3 months preceding enrollment 3. Physical or cognitive impairment that prevents completion of trial assessments 4. Inability to provide written informed consent
Where it's running
-
Peking Union Medical College Hospital ICU Units
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Yuankai Zhou，Associate Professor, Department of Critical Care Medicine, MD
- Email: zhouyuankai@pumch.cn
- Phone: +86-10-69152300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
-
Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases
This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.